CNS Drugs

, Volume 28, Issue 7, pp 641–648

Natalizumab: Risk Stratification of Individual Patients with Multiple Sclerosis

Review Article

Abstract

At present, three risk factors for the development of progressive multifocal leukoencephalopathy (PML) in natalizumab-treated patients have been identified: the presence of antibodies against JC virus (JCV); the duration of natalizumab treatment, especially if longer than 2 years; and the use of immunosuppressants prior to receiving natalizumab. The most commonly used strategy to assess the individual PML risk includes serum anti-JCV antibody testing. Based on the knowledge on all known risk factors, an algorithm for PML risk stratification has been proposed, where patients with the highest PML risk are those with positive anti-JCV antibodies, treatment duration longer than 2 years, with or without prior history of immunosuppression. These patients would have an approximate incidence of PML of 11.1 (with prior immunosuppression) or 4.6 (without prior immunosuppression) cases per 1,000 patients treated with natalizumab (and treatment duration longer than 2 years). In this review, new data on PML risk factors and possible new strategies for PML risk stratification are discussed.

References

  1. 1.
    Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2003;348(1):15–23.PubMedCrossRefGoogle Scholar
  2. 2.
    Polman CH, O’Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899–910.PubMedCrossRefGoogle Scholar
  3. 3.
    Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):911–23.PubMedCrossRefGoogle Scholar
  4. 4.
    Horga A, Castillo J, Rio J, et al. An observational study of the effectiveness and safety of natalizumab in the treatment of multiple sclerosis. Rev Neurol. 2011;52(6):321–30.PubMedGoogle Scholar
  5. 5.
    Langer-Gould A, Atlas SW, Green AJ, Bollen AW, Pelletier D. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med. 2005;353(4):375–81.PubMedCrossRefGoogle Scholar
  6. 6.
    Zurhein G, Chou SM. Particles resembling papova viruses in human cerebral demyelinating disease. Science. 1965;148(3676):1477–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Sorensen PS, Bertolotto A, Edan G, et al. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. Mult Scler. 2012;18(2):143–52.PubMedCrossRefGoogle Scholar
  8. 8.
    Biogen Idec® Official Site. http://www.biogenidec-international.com/tysabri_fact_sheet.aspx?ID=4698. Accessed Oct 2013.
  9. 9.
    PubMed® Official Site. http://www.ncbi.nlm.nih.gov/pubmed. Accessed Oct 2013.
  10. 10.
    Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80(15):1430–8.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    White MK, Khalili K. Pathogenesis of progressive multifocal leukoencephalopathy—revisited. J Infect Dis. 2011;203(5):578–86.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Yousry TA, Pelletier D, Cadavid D, et al. Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. Ann Neurol. 2012;72(5):779–87.PubMedCrossRefGoogle Scholar
  13. 13.
    Iacobaeus E, Ryschkewitsch C, Gravell M, et al. Analysis of cerebrospinal fluid and cerebrospinal fluid cells from patients with multiple sclerosis for detection of JC virus DNA. Mult Scler. 2009;15(1):28–35.PubMedCrossRefGoogle Scholar
  14. 14.
    Cinque P, Koralnik IJ, Clifford DB. The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol. 2003;9(Suppl 1):88–92.PubMedCrossRefGoogle Scholar
  15. 15.
    Boster AL, Nicholas JA, Topalli I, et al. Lessons learned from fatal progressive multifocal leukoencephalopathy in a patient with multiple sclerosis treated with natalizumab. JAMA Neurol. 2013;70(3):398–402.PubMedCrossRefGoogle Scholar
  16. 16.
    Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–52.PubMedCrossRefGoogle Scholar
  17. 17.
    Bloomgren G, Richman S, Hotermans C, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med. 2012;366(20):1870–80.PubMedCrossRefGoogle Scholar
  18. 18.
    Chesters PM, Heritage J, McCance DJ. Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. J Infect Dis. 1983;147(4):676–84.PubMedCrossRefGoogle Scholar
  19. 19.
    Egli A, Infanti L, Dumoulin A, et al. Prevalence of polyomavirus BK and JC infection and replication in 400 healthy blood donors. J Infect Dis. 2009;199(6):837–46.PubMedCrossRefGoogle Scholar
  20. 20.
    Zanotta N, Delbue S, Rossi T, et al. Molecular epidemiology of JCV genotypes in patients and healthy subjects from Northern Italy. J Med Virol. 2013;85(7):1286–92.PubMedCrossRefGoogle Scholar
  21. 21.
    Havla J, Berthele A, Kumpfel T, et al. Co-occurrence of two cases of progressive multifocal leukoencephalopathy in a natalizumab “infusion group”. Mult Scler. 2013;19(9):1213–5.PubMedCrossRefGoogle Scholar
  22. 22.
    Reid CE, Li H, Sur G, et al. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis. 2011;204(2):237–44.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Bellizzi A, Anzivino E, Rodio DM, et al. Human Polyomavirus JC monitoring and noncoding control region analysis in dynamic cohorts of individuals affected by immune-mediated diseases under treatment with biologics: an observational study. Virol J. 2013;10(1):298.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Gorelik L, Reid C, Testa M, et al. Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis. 2011;204(1):103–14.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Warnke C, Ramanujam R, Plavina T, et al. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry. 2013;84(11):1199–205.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Perkins MR, Ryschkewitsch C, Liebner JC, et al. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy. PLoS pathog. 2012;8(11):e1003014.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Warnke C, Mausberg AK, Stettner M, et al. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology. 2013;81(16):1400–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Schwab N, Schneider-Hohendorf T, Posevitz V, et al. L-Selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology. 2013;81(10):865–71.PubMedCrossRefGoogle Scholar
  29. 29.
    Plavina T, Berman M, Njenga M, et al. Multi-site analytical validation of an assay to detect anti-JCV antibodies in human serum and plasma. J Clin Virol. 2012;53(1):65–71.PubMedCrossRefGoogle Scholar
  30. 30.
    Bozic C, Richman S, Plavina T, et al. Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. Ann Neurol. 2011;70(5):742–50.PubMedCrossRefGoogle Scholar
  31. 31.
    Lee P, Plavina T, Castro A, et al. A second-generation ELISA (STRATIFY JCV DxSelect) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification. J Clin Virol. 2013;57(2):141–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Gorelik L, Lerner M, Bixler S, et al. Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol. 2010;68(3):295–303.PubMedCrossRefGoogle Scholar
  33. 33.
    Berger JR, Houff SA, Gurwell J, Vega N, Miller CS, Danaher RJ. JC virus antibody status underestimates infection rates. Ann Neurol. 2013;74(1):84–90.PubMedCrossRefGoogle Scholar
  34. 34.
    Major EO, Frohman E, Douek D. JC viremia in natalizumab-treated patients with multiple sclerosis. N Engl J Med. 2013;368(23):2240–1.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Laroni A, Giacomazzi CG, Grimaldi L, et al. Urinary JCV-DNA testing during natalizumab treatment may increase accuracy of PML risk stratification. J Neuroimmune Pharmacol. 2012;7(3):665–72.PubMedCrossRefGoogle Scholar
  36. 36.
    Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog. 2009;5(3):e1000363.PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Lin J, Bettin P, Lee JK, Ho JK, Sadiq SA. Cerebrospinal fluid and serum JC virus antibody detection in multiple sclerosis patients treated with natalizumab. J Neuroimmunol. 2013;261(1–2):123–8.PubMedCrossRefGoogle Scholar
  38. 38.
    Plavina T, Subramanyam M, Bloomgren G, Richman S, Pace A, Lee S, Schlain B, Campagnolo D, Ticho B. Use of JC virus antibody index to stratify risk of progressive multifocal leukoencephalopathy in natalizumab-treated patients with multiple sclerosis [oral communication]. ENS Congress, Barcelona, June 2013.Google Scholar

Copyright information

© Springer International Publishing Switzerland 2014

Authors and Affiliations

  1. 1.Multiple Sclerosis Centre of Catalonia (Cemcat), Department of Neurology-NeuroimmunologyVall d’Hebron University HospitalBarcelonaSpain

Personalised recommendations